The most common adverse event with AMG 785 in the phase II trial was injection site reaction (9.8%). No fatal adverse events were reported. The maximum tolerated dose has not been identified, with the monthly 210-mg dose to be carried forward into subsequent phase III trials, Dr. McClung said.
The trial was funded by Amgen and UCB Pharma. Dr. McClung reported financial relationships with Amgen, Lilly, Merck, Novartis, and Warner Chilcott.
CORRECTION 10/19/12: The headline for this story misstated the name of the investigational drug. The headline should read "Antisclerostin Therapy AMG 785 Scores Big in Osteoporosis Arena."